Davunetide: Side Effects

Safety Overview#

Davunetide demonstrated a favorable safety profile in the phase 2/3 PSP trial, with adverse event rates comparable to placebo. The intranasal route of administration was well tolerated over 52 weeks of treatment.

Clinical Trial Safety Data#

In the Boxer et al. (2014) trial, 157 patients received davunetide 30 mg BID intranasally for up to 52 weeks. The adverse event profile was similar between davunetide and placebo groups. Common adverse events included nasal irritation and headache, most of which were mild in severity.

Intranasal Tolerability#

The nasal spray formulation was generally well tolerated, with local nasal effects (irritation, dryness) being the most common treatment-related complaints. These were typically mild and did not lead to treatment discontinuation.

Safety Profile Context#

Davunetide belongs to the Neuroprotective category of research peptides. Understanding the side effect profile of Davunetide is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Davunetide. Side effect severity and frequency are based on available clinical data.

Nasal irritation#

Severity: mild | Frequency: common

Mild nasal irritation associated with intranasal delivery, generally well tolerated.

Headache#

Severity: mild | Frequency: common

Headache reported at rates comparable to placebo in the PSP trial.

Contraindications#

The following contraindications have been identified for Davunetide based on available research and pharmacological considerations:

• Not approved for any therapeutic use
• Known hypersensitivity to davunetide or formulation excipients

Individuals with any of these conditions should not use Davunetide without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Davunetide:

• No significant drug interactions identified in clinical trials
• Theoretical interaction with other microtubule-targeting agents (taxanes, vinca alkaloids)

Drug interaction studies for Davunetide remain limited. Researchers should exercise caution when combining Davunetide with other compounds and consult relevant pharmacological references.

Related Reading#

• Davunetide overview and research guide
• Davunetide dosing protocols
• Davunetide risks and legal status